We are live on ! Find out more
BIOT

Biotech Acquisition Company Class A Ordinary Shares
BIOT

Delisted

BIOT was delisted on the 2nd of February, 2023.

Back to rankings

51 hedge funds and large institutions have $121M invested in Biotech Acquisition Company Class A Ordinary Shares in 2021 Q2 according to their latest regulatory filings, with 24 funds opening new positions, 10 increasing their positions, 1 reducing their positions, and 1 closing their positions.

New
Increased
Maintained
Reduced
Closed

2,300% more first-time investments, than exits

New positions opened: 24 | Existing positions closed: 1

900% more repeat investments, than reductions

Existing positions increased: 10 | Existing positions reduced: 1

82% more funds holding

Funds holding: 28 → 51 (+23)

72% more capital invested

Capital invested by funds: $70M → $121M (+$50.7M)

Holders
51
Holders Change
+23
Holders Change %
+82.14%
% of All Funds
0.89%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
24
Increased
10
Reduced
1
Closed
1
Calls
$86K
Puts
–
Net Calls
+$86K
Net Calls Change
+$86K

Top Buyers

Rank Fund Capital Flow
1
LA
Linden Advisors
New York
+$6.6M
2
SCM
Saba Capital Management
New York
+$5.73M
3
PC
Periscope Capital
Ontario, Canada
+$5M
4
DCM
DG Capital Management
New York
+$4.37M
5
RCM
Radcliffe Capital Management
Pennsylvania
+$3.94M

Top Sellers

Rank Fund Capital Flow
1
KCM
Kingstown Capital Management
New York
-$2.92M
2
TCM
Tenor Capital Management
New York
-$1.33M
Name Holding Trade Value Shares
Change 		Change in
Stake
CCP
1
Corbin Capital Partners
New York
$8.97M – – –
Citadel Advisors
2
Citadel Advisors
Florida
$8.68M +$22.7K +2,340 +0.3%
PC
3
Periscope Capital
Ontario, Canada
$7.35M +$5M +514,494 +210%
LA
4
Linden Advisors
New York
$6.57M +$6.6M +678,849 New
PAMP
5
Polar Asset Management Partners
Ontario, Canada
$5.8M – – –
SCM
6
Saba Capital Management
New York
$5.7M +$5.73M +589,886 New
ACM
7
Atalaya Capital Management
New York
$5.38M – – –
Blackstone Inc
8
Blackstone Inc
New York
$4.83M – – –
DCM
9
DG Capital Management
New York
$4.35M +$4.37M +450,000 New
RCM
10
Radcliffe Capital Management
Pennsylvania
$3.92M +$3.94M +405,900 New
FTCM
11
Fir Tree Capital Management
New York
$3.87M +$972K +100,000 +33%
Nomura Holdings
12
Nomura Holdings
Japan
$3.86M +$3.89M +400,000 New
DKCM
13
Davidson Kempner Capital Management
New York
$3.79M +$3.82M +392,798 New
Hudson Bay Capital Management
14
Hudson Bay Capital Management
Connecticut
$3.77M +$1.85M +189,930 +95%
KSCM
15
Kamunting Street Capital Management
Florida
$3.07M +$3.09M +317,924 New
MP
16
Mangrove Partners
Connecticut
$2.9M – – –
SC
17
Sculptor Capital
New York
$2.9M – – –
Deutsche Bank
18
Deutsche Bank
Germany
$2.42M +$2.43M +250,000 New
CC
19
Centiva Capital
New York
$2.4M +$2.41M +248,000 New
Goldman Sachs
20
Goldman Sachs
New York
$2.27M +$1.7M +174,915 +291%
Bank of Montreal
21
Bank of Montreal
Ontario, Canada
$1.94M +$1.94M +200,000 New
CH
22
CVI Holdings
Delaware
$1.93M – – –
WAM
23
Wolverine Asset Management
Illinois
$1.8M +$1.79M +184,102 +11,004%
D.E. Shaw & Co
24
D.E. Shaw & Co
New York
$1.78M +$1.78M +183,648 New
Bank of America
25
Bank of America
North Carolina
$1.61M +$243K +25,000 +18%
1
2 3

BIOT Hedge Fund Activity: Q2 2021 in Review

51 of the 5,746 institutional investors tracked by Wall St. Rank reported a position in Biotech Acquisition Company Class A Ordinary Shares (BIOT) for Q2 2021, worth a combined $121M — up 72% from $70M a quarter earlier.

Buyers outnumbered sellers: 24 funds opened new BIOT positions and 1 closed out — a net gain of 23 holders — while 10 added to existing stakes and 1 trimmed.

The largest buyer was Linden Advisors, opening a new position worth an estimated $6.6M. The largest seller was Kingstown Capital Management, exiting entirely with an estimated $2.92M sold.

  • 51 institutional investors held Biotech Acquisition Company Class A Ordinary Shares (BIOT) as of Q2 2021, up from 28 in Q1 2021.
  • Funds reported $121M of Biotech Acquisition Company Class A Ordinary Shares stock for Q2 2021, up 72% quarter-over-quarter.
  • 24 funds opened new Biotech Acquisition Company Class A Ordinary Shares positions in Q2 2021 and 1 closed out, a net change of +23 holders.
  • The largest Biotech Acquisition Company Class A Ordinary Shares buyer in Q2 2021 was Linden Advisors, an estimated $6.6M added.
  • The largest Biotech Acquisition Company Class A Ordinary Shares seller in Q2 2021 was Kingstown Capital Management, an estimated $2.92M sold.

Based on aggregated 13F filings for Q2 2021.